Tag:

COPD

Latest Headlines

Latest Headlines

Study shows COPD device effective in deterring mucus buildup

Data from a study on a new nondrug treatment for chronic obstructive pulmonary disease offered evidence that Trudell Medical's Aerobika OPEP hand-held device is beneficial for COPD patients with recurring mucus buildup.

Boehringer's next-gen COPD treatment hits the mark in Phase III

Boehringer Ingelheim met its main goals in a late-stage study on a new COPD treatment, clearing the way for regulatory approvals and a bout with rival GlaxoSmithKline.

AstraZeneca's self-styled 'blockbuster' benralizumab tanks in severe COPD study

AstraZeneca was forced to concede a clinical defeat on Monday, noting that one of its top respiratory drugs in the clinic failed a study for severe chronic obstructive pulmonary disease. But while investigators also flagged a higher rate of adverse events for benralizumab than the placebo arm, the pharma giant shows no signs of backing away from a treatment it's billed as a potential $2 billion per year product.

Propeller Health gets $14.5M Series B for smart inhaler, app combo

It can be difficult for patients with respiratory ailments to track their use of rescue medications. An inhaler sensor from Propeller Health does just that--serving as a remote monitor of drug use and feeding into a mobile app that tracks and analyzes medication use. The app even predicts when patients are likely to have difficulty, based on prior experience, and can be used to ensure proper inhaler usage, a common issue.

Mist formulation of Boehringer Ingelheim's COPD inhaler gets advisory committee nod

The FDA's Pulmonary-Allergy Drugs Advisory Committee voted 10-3 to recommend approval of Boehringer Ingelheim's mist formulation of its dry-powder inhalable treatment for chronic obstructive pulmonary disease.

Can Boehringer carve out space in a crowded COPD market with new approval?

The COPD market has its fair share of contenders, but that's not stopping Boehringer Ingelheim from joining the party. The German drugmaker has nabbed FDA approval for its own entrant, which will go up against the likes of Glaxo's aging giant Advair in a market-share showdown. But despite the competition, BI is hoping it can still find its corner.

Boehringer plays catch-up in COPD with its latest FDA approval

The FDA approved Boehringer Ingelheim's COPD treatment Striverdi Respimat, a once-a-day inhaler the German drugmaker hopes can contend in a crowded respiratory market.

GlaxoSmithKline and Theravance eye Phase III for another COPD contender

The blockbuster duo of GlaxoSmithKline and Theravance are pushing a new respiratory combo therapy into late-stage study, pooling the active ingredients from its last two approved COPD treatments to create a once-daily inhaler.

Novartis, Boehringer vie for COPD market share with combo meds

Rivals Novartis and Boehringer Ingelheim are touting positive results for their combination COPD treatments, duking it out with GlaxoSmithKline for dominance of a market that could reach $14 billion by 2018.

Novartis hopes new COPD study data will draw patients from Glaxo's Advair

Novartis' generic of Advair in Europe is already a thorn in GlaxoSmithKline's side when it comes to sales of the declining blockbuster. Now, it says, another of its lung drugs has turned out positive study data that show its non-inferiority to Glaxo's top seller in COPD, and with its more convenient dosing regimen, it could prompt patients on Advair to make the switch.